KiOmed Pharma, a subsidiary of KitoZyme, has received approval from European authorities to market Kytogen Defend, the world's first aesthetic injectable made from non-animal chitosan, thus opening up a new market valued at $1.5 billion and experiencing significant growth. (translated)











